Utility of Mobile Health Applications, Wearable Devices, and Patient Generated Health Data in Menopause Research
Author(s)
Joehl Nguyen, PhD1, Kristen Rosen, PhD2, Senka Djordjevic, MD3, Ann-Kathrin Frenz, MsC4, Anna-Katharina Meinecke, MSc, PhD4, Kelly Genga, MD, PhD5, Bahiyyih Schmalenberg, MSc6, Nils Schoof, PhD7;
1Bayer Healthcare Pharmaceuticals Inc., Whippany, NJ, USA, 2Evidation Health, Inc., San Mateo, CA, USA, 3Bayer Consumer Care AG, Basel, Switzerland, 4Bayer AG, Wuppertal, Germany, 5Bayer SA, Sao Paulo, Brazil, 6Bayer Inc., Mississauga, ON, Canada, 7Bayer AG, Berlin, Germany
1Bayer Healthcare Pharmaceuticals Inc., Whippany, NJ, USA, 2Evidation Health, Inc., San Mateo, CA, USA, 3Bayer Consumer Care AG, Basel, Switzerland, 4Bayer AG, Wuppertal, Germany, 5Bayer SA, Sao Paulo, Brazil, 6Bayer Inc., Mississauga, ON, Canada, 7Bayer AG, Berlin, Germany
Presentation Documents
OBJECTIVES: Health data generated directly from women can improve understanding of menopause symptom burden. This study assessed the feasibility of using mobile applications and wearable devices in menopause real-world research, with specific focus on vasomotor symptoms (VMS) and sleep measures.
METHODS: A cross-sectional survey was piloted through the Evidation mobile application, where users are engaged in tracking health behaviors. Women aged 40-65 who reported having VMS in the last 30 days, had their last menstrual period at least 12 months prior, had wearable data on sleep measures for 70% of the past 30 days, and consented to the survey and linkage to wearable data. Exclusion criteria included current breastfeeding, hormonal contraceptive use, hypothalamic amenorrhea, or cancer therapy induced menopause symptoms. Survey items included VMS burden and sleep disruption. Wearable data include sleep duration, wakefulness after sleep onset, and time in bed. We assessed recruitment time, survey completion, and descriptive analyses of VMS burden and sleep measures.
RESULTS: 102 women met inclusion criteria and completed the survey with a median completion time of 14.71 minutes [interquartile range (IQR) 9.8 - 26.9]. Mean age was 56.1 years; 52% of participants identified as White, 20% as Black or African American, 8% as Asian, and 14% as multiracial or other. Sleep disturbance, daytime VMS, and nighttime VMS in the past 30 days were reported among 62.8%, 72.6%, and 85.3% of participants, respectively. Most participants (97-100%) had at least 70% data availability for wearable measures. Median sleep duration and awake time after sleep onset was 377.2 (IQR 342.3 - 411.45) minutes and 52.7 (45.9 - 63.6) minutes, respectively.
CONCLUSIONS: Mobile health applications may be an innovative approach to gain insights on symptom burden during menopause. Sleep data generated directly from women through wearable devices may enable further research into the association between objective sleep measures and other menopausal symptoms.
METHODS: A cross-sectional survey was piloted through the Evidation mobile application, where users are engaged in tracking health behaviors. Women aged 40-65 who reported having VMS in the last 30 days, had their last menstrual period at least 12 months prior, had wearable data on sleep measures for 70% of the past 30 days, and consented to the survey and linkage to wearable data. Exclusion criteria included current breastfeeding, hormonal contraceptive use, hypothalamic amenorrhea, or cancer therapy induced menopause symptoms. Survey items included VMS burden and sleep disruption. Wearable data include sleep duration, wakefulness after sleep onset, and time in bed. We assessed recruitment time, survey completion, and descriptive analyses of VMS burden and sleep measures.
RESULTS: 102 women met inclusion criteria and completed the survey with a median completion time of 14.71 minutes [interquartile range (IQR) 9.8 - 26.9]. Mean age was 56.1 years; 52% of participants identified as White, 20% as Black or African American, 8% as Asian, and 14% as multiracial or other. Sleep disturbance, daytime VMS, and nighttime VMS in the past 30 days were reported among 62.8%, 72.6%, and 85.3% of participants, respectively. Most participants (97-100%) had at least 70% data availability for wearable measures. Median sleep duration and awake time after sleep onset was 377.2 (IQR 342.3 - 411.45) minutes and 52.7 (45.9 - 63.6) minutes, respectively.
CONCLUSIONS: Mobile health applications may be an innovative approach to gain insights on symptom burden during menopause. Sleep data generated directly from women through wearable devices may enable further research into the association between objective sleep measures and other menopausal symptoms.
Conference/Value in Health Info
2025-05, ISPOR 2025, Montréal, Quebec, CA
Value in Health, Volume 28, Issue S1
Code
PCR74
Topic
Patient-Centered Research
Topic Subcategory
Patient-reported Outcomes & Quality of Life Outcomes
Disease
No Additional Disease & Conditions/Specialized Treatment Areas, SDC: Reproductive & Sexual Health